Kura Oncology (NASDAQ:KURA) Price Target Lowered to $14.00 at UBS Group

Kura Oncology (NASDAQ:KURA) had its price objective decreased by analysts at UBS Group from $27.00 to $14.00 in a note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. UBS Group’s target price suggests a potential upside of 85.55% from the stock’s current price.

Several other research analysts have also weighed in on the company. Cantor Fitzgerald raised Kura Oncology to a “strong-buy” rating in a research report on Tuesday. StockNews.com raised Kura Oncology from a “sell” rating to a “hold” rating in a research report on Thursday, February 27th. Jefferies Financial Group lowered their price objective on shares of Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research report on Thursday, November 21st. Bank of America reduced their target price on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a research report on Friday, November 22nd. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $28.00 price target on shares of Kura Oncology in a report on Thursday, February 6th. Four analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Kura Oncology has an average rating of “Moderate Buy” and a consensus price target of $25.50.

Kura Oncology Price Performance

Shares of NASDAQ KURA traded up $0.18 on Thursday, hitting $7.55. The company’s stock had a trading volume of 290,880 shares, compared to its average volume of 1,567,358. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. Kura Oncology has a 12-month low of $6.98 and a 12-month high of $24.17. The company has a market capitalization of $586.73 million, a price-to-earnings ratio of -3.18 and a beta of 0.85. The stock has a 50 day moving average of $8.04 and a 200-day moving average of $13.51.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.65) by $0.43. The firm had revenue of $53.88 million for the quarter, compared to analyst estimates of $57.96 million. As a group, research analysts predict that Kura Oncology will post -2.44 EPS for the current year.

Insider Activity

In other news, insider Mollie Leoni sold 4,963 shares of the company’s stock in a transaction that occurred on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now directly owns 88,253 shares of the company’s stock, valued at approximately $694,551.11. This represents a 5.32 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Thomas James Doyle sold 4,949 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the transaction, the senior vice president now owns 88,193 shares of the company’s stock, valued at $694,078.91. This represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 11,729 shares of company stock worth $92,307. 5.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Harbor Capital Advisors Inc. grew its stake in shares of Kura Oncology by 21.9% in the third quarter. Harbor Capital Advisors Inc. now owns 47,295 shares of the company’s stock worth $924,000 after purchasing an additional 8,505 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its position in shares of Kura Oncology by 35.2% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 29,655 shares of the company’s stock worth $579,000 after buying an additional 7,722 shares in the last quarter. Intech Investment Management LLC acquired a new stake in shares of Kura Oncology in the 3rd quarter worth approximately $298,000. Charles Schwab Investment Management Inc. boosted its holdings in shares of Kura Oncology by 2.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 624,952 shares of the company’s stock valued at $12,212,000 after acquiring an additional 14,106 shares in the last quarter. Finally, Algert Global LLC increased its stake in shares of Kura Oncology by 4.4% during the third quarter. Algert Global LLC now owns 272,276 shares of the company’s stock valued at $5,320,000 after acquiring an additional 11,493 shares during the period.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.